Literature DB >> 21916596

Human pluripotent stem cells for genetic disease modeling and drug screening.

Morgane Gauthier1, Yves Maury, Marc Peschanski, Cécile Martinat.   

Abstract

Considerable hope surrounds the use of disease-specific pluripotent stem cells, which can differentiate into any cell type, as starting materials to generate models of human disease that will allow exploration of pathological mechanisms and the search for new treatments. Disease-specific human embryonic stem cells have provided a useful source for studying certain disease states. However, reprogramming of human somatic cells that use readily accessible tissue, such as skin or blood, to generate embryonic-like induced pluripotent stem cells has opened new perspectives for modeling and understanding a larger number of human pathologies. Here, we examine the challenges in creating a disease model from human pluripotent stem cells, and describe their use to model both cell-autonomous and non-cell-autonomous mechanisms, the need for adequate control experiments and the genetic limitations of human induced pluripotent stem cells. Progress in these areas will substantially accelerate effective application of disease-specific human pluripotent stem cells for drug screening.

Entities:  

Mesh:

Year:  2011        PMID: 21916596     DOI: 10.2217/rme.11.46

Source DB:  PubMed          Journal:  Regen Med        ISSN: 1746-0751            Impact factor:   3.806


  3 in total

1.  Targeted Elimination of Tumorigenic Human Pluripotent Stem Cells Using Suicide-Inducing Virus-like Particles.

Authors:  Antonio Rampoldi; Stephen N Crooke; Marcela K Preininger; Rajneesh Jha; Joshua Maxwell; Lingmei Ding; Paul Spearman; M G Finn; Chunhui Xu
Journal:  ACS Chem Biol       Date:  2018-07-19       Impact factor: 5.100

2.  Generation of induced pluripotent stem cells from renal tubular cells of a patient with Alport syndrome.

Authors:  Wenbiao Chen; Jianrong Huang; Xiangqi Yu; Xiaocong Lin; Yong Dai
Journal:  Int J Nephrol Renovasc Dis       Date:  2015-08-21

3.  Targeted Delivery of Secretory Promelittin via Novel Poly(lactone-co-β-amino ester) Nanoparticles for Treatment of Breast Cancer Brain Metastases.

Authors:  Yu Zhou; Shenqi Zhang; Zeming Chen; Youmei Bao; Ann T Chen; Wendy C Sheu; Fuyao Liu; Zhaozhong Jiang; Jiangbing Zhou
Journal:  Adv Sci (Weinh)       Date:  2020-01-19       Impact factor: 16.806

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.